{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lipid-modification-cvd-prevention/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field f5221691-c3ba-48f1-8615-1eb68f4b1f58 --><h2>Update</h2><!-- end field f5221691-c3ba-48f1-8615-1eb68f4b1f58 -->","summary":null,"htmlStringContent":"<!-- begin item 635b92e6-857f-43c6-988a-b7d955468ef4 --><!-- end item 635b92e6-857f-43c6-988a-b7d955468ef4 -->","topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","lastRevised":"Last revised in October 2020","chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","fullItemName":"Management","slug":"management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"184e9f02-cec5-5813-a428-f3b70683deda","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"1f343fdd-9cfc-50f6-ad66-9c51ecf0311b","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 451a337f-8988-4cd5-947f-3c4386d6f8d6 --><h3>New evidence</h3><!-- end field 451a337f-8988-4cd5-947f-3c4386d6f8d6 -->","summary":null,"htmlStringContent":"<!-- begin item 581dcdeb-ee95-4e0a-8238-8285de6d40a7 --><!-- begin field 04986b08-8e8a-44dd-96f0-64d566551c46 --><h3>Evidence-based guidelines</h3><!-- end field 04986b08-8e8a-44dd-96f0-64d566551c46 --><!-- begin field ec5453a4-9b9d-49cf-82a7-72a525f0cc92 --><p>No new evidence-based guidelines since 1 August 2019.</p><!-- end field ec5453a4-9b9d-49cf-82a7-72a525f0cc92 --><!-- begin field e43466b7-e4ab-46dc-ae3d-20b9f0726227 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field e43466b7-e4ab-46dc-ae3d-20b9f0726227 --><!-- begin field 69a22392-5d18-478a-b699-b56a04223d75 --><p>No new health technology assessments published since 1 August 2019.</p><!-- end field 69a22392-5d18-478a-b699-b56a04223d75 --><!-- begin field 0d6a32f3-25d4-48e1-8466-72790d4448e0 --><h3>Economic appraisals</h3><!-- end field 0d6a32f3-25d4-48e1-8466-72790d4448e0 --><!-- begin field 95c5c21b-ff5f-4a30-b679-ab9416d0a606 --><p>No new economic appraisals relevant to England since 1 August 2019.</p><!-- end field 95c5c21b-ff5f-4a30-b679-ab9416d0a606 --><!-- begin field 3e2c28fc-d853-4807-ad10-81eaeba4d619 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 3e2c28fc-d853-4807-ad10-81eaeba4d619 --><!-- begin field 5bb28a8f-7c8f-4c4f-977c-6d91ce1b06f0 --><ul><li>Adams, S.P., Alaeiilkhchi, N., Wright, J.M (2020) <em>Pitavastatin for lowering lipids.</em> Cochrane Library. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"f54e17ef-e366-47d9-9130-ac4100b3bb2a\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012735.pub2/full\" data-hyperlink-id=\"380404eb-e150-4370-914c-ac4100b3bc01\">Free Full-text</a>]</li></ul><!-- end field 5bb28a8f-7c8f-4c4f-977c-6d91ce1b06f0 --><!-- begin field e9268777-a7c7-4736-bbac-1852e67af9e6 --><h3>Primary evidence</h3><!-- end field e9268777-a7c7-4736-bbac-1852e67af9e6 --><!-- begin field accc5728-e677-44cf-a95a-9f15e9c40daa --><p>No new primary evidence published since 1 August 2019.</p><!-- end field accc5728-e677-44cf-a95a-9f15e9c40daa --><!-- end item 581dcdeb-ee95-4e0a-8238-8285de6d40a7 -->","subChapters":[]},{"id":"181d2c75-98e4-5db8-8fe6-d84c8813c176","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field b57eac86-95bb-4c0f-a818-27dbe7549954 --><h3>New policies</h3><!-- end field b57eac86-95bb-4c0f-a818-27dbe7549954 -->","summary":null,"htmlStringContent":"<!-- begin item 6bb36fc0-a9d7-4f56-9efa-beacb6d9ea5a --><!-- begin field f3b3b89b-e4a9-4924-8a2c-f9c0c1c6e6a0 --><p>No new national policies or guidelines since 1 August 2019.</p><!-- end field f3b3b89b-e4a9-4924-8a2c-f9c0c1c6e6a0 --><!-- end item 6bb36fc0-a9d7-4f56-9efa-beacb6d9ea5a -->","subChapters":[]},{"id":"3b4f6376-a5fd-5471-92d8-1be5a576ccc0","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 9aa4e4ee-4396-409c-a26b-13554f1cdce9 --><h3>New safety alerts</h3><!-- end field 9aa4e4ee-4396-409c-a26b-13554f1cdce9 -->","summary":null,"htmlStringContent":"<!-- begin item 465e48ff-acc9-4ffd-9609-b8126215e668 --><!-- begin field 73790d99-13bb-4f50-b1ff-066c6bdd8fba --><p>No new safety alerts since 1 August 2019.</p><!-- end field 73790d99-13bb-4f50-b1ff-066c6bdd8fba --><!-- end item 465e48ff-acc9-4ffd-9609-b8126215e668 -->","subChapters":[]},{"id":"39d0750e-aa60-5a81-a842-fa164cf6dc3f","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field f1dee9e6-9e50-4f31-98cd-128dcea6e30f --><h3>Changes in product availability</h3><!-- end field f1dee9e6-9e50-4f31-98cd-128dcea6e30f -->","summary":null,"htmlStringContent":"<!-- begin item a0220279-a721-48ea-a249-e1d8dd030073 --><!-- begin field 95ebb062-8036-4bd5-ba52-94ccba4fc385 --><ul><li>Bempedoic acid lowers low-density lipoprotein cholesterol by inhibiting cholesterol synthesis in the liver; and will be available as 180 mg film-coated tablets. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/nilemdo\" data-hyperlink-id=\"94454d04-802b-47c7-b415-ab6d00c6994a\">here</a>.</li><li>Nilemdo is licensed for treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, either as monotherapy or in combination with a statin. See more <a href=\"https://www.medicines.org.uk/emc/product/11743/smpc\" data-hyperlink-id=\"ff9e2cda-df92-479c-934f-ac3300d1b7f7\">here</a>. </li><li>Nustendi is licensed for treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, either as monotherapy or in combination with a statin. See more <a href=\"https://www.medicines.org.uk/emc/product/11744/smpc\" data-hyperlink-id=\"56e4fa7d-62a7-4578-a5d8-ac3300d1b869\">here</a>.</li></ul><!-- end field 95ebb062-8036-4bd5-ba52-94ccba4fc385 --><!-- end item a0220279-a721-48ea-a249-e1d8dd030073 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}